TUC-S.R.L.
24.4.2024 09:36:30 CEST | Business Wire | Press release
TUC S.r.l., the Deep Tech Company known for TUC.technology, launches a fundamental evolution of its offer, TUC.tiny™. This mobility revolution comes with all the features at the base of the TUC.technology patent, issued in over 140 countries worldwide. A small jewel based on TUC's three technological pillars, mechanical structuring, electronic management and data exchange, designed to also interface with consumer electronics thanks to the integration of USB Type-C technology. TUC.tiny™ becomes the USB of Mobility, a solution that aims to reinvent the interaction between users and vehicles bringing together mobility and everyday life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424672317/en/
TUC dashboard (Photo: Business Wire)
A real blank canvas, which can be transformed and customized countless times thanks to TUC.tiny™ and TUC.technology™, flexibly adapting to every need and preference. With TUC's innovative patented technology, personal devices such as smartphones, tablets, speakers and voice automation systems can be securely integrated. At the same time, automotive-specific elements such as dashboards, switches for driving mode selection and climate control, navigation systems with integrated cameras, harmonize with accessories that can be used both in the car and at home, such as fragrance diffusers and ambient lights.
TUC S.r.l. is at the forefront of mobility innovation, specialized in the development of modular vehicle solutions that aims to simplify and revolutionize the concept of vehicles, from a defined product to a definable experience. Distinguishing itself for technological excellence at international level, TUC has achieved significant recognition. With the launch of TUC 3.0 in 2023, the company is setting new standards in the industry by partnering with leading global OEMs.
With TUC.tiny™ and its advanced interface – which includes physical fixing, electrical and data transfer connectivity – any device can be integrated into the modular design of the dashboard, making it immediately operational. This allows users to customize their mobile space with extreme ease and freedom. TUC.tiny™ is designed to support all everyday devices that have a USB Type-C connection. These can be integrated into TUC.tiny™ through a state-of-the-art module. The proposed solution stands out for its ability to blend harmoniously into any part of the vehicle, both inside and outside, ensuring direct and simple installation, both in the production phase and after-sales, eliminating the need to adopt inefficient and unsafe solutions such as suction cups or other impractical and unreliable systems. In addition, the robustness of TUC.tiny™ is ensured by a mechanical or electro-actuated locking system, which introduces the novelty of security offered by NFC technology for reliable control of locking and unlocking functions.
"We are proud of the results achieved thanks to our constant commitment over the last few years," comments Ludovico Campana, Inventor and CEO of TUC. “TUC.tiny™ represents our promise for the future; A vision of a world where technology and mobility come together in personalized experiences, designed around the needs of everyone. With TUC.technology®, we enable a paradigm shift, giving vehicle manufacturers tools to simplify development, engineering, and manufacturing, while enabling new business models that enhance continuous post-production customization. Our goal is that it is not the user who adapts to the life cycle of the vehicle, but that the vehicle can evolve to meet the changing needs of its user. We are thrilled with the results obtained by customers who are experimenting and adopting our technology, testifying to the validity and effectiveness of our work – continues Campana – This is the future that TUC S.r.l. is building: a mobility ecosystem where every innovation is guided by the values of democratization of technology, customization and sustainability, with the ambition to overcome current boundaries and explore new possibilities for a more connected and sustainable society. responsible."
The introduction of TUC.tiny™ is the completion of TUC.technology's offering. It marks a step towards the "democratization" of technology. The gateway to an advanced mobility experience becomes wider, easily accommodating the smart objects that animate our daily lives. This isn't just a technological advance; is TUC's invitation to imagine and build together the future of mobility, a world where technology unites us, improving every aspect of our daily journey.
ABOUT TUC.technology
TUC S.r.l. is a Deep-Tech company at the forefront of mobility innovation, specialized in the development of modular vehicle solutions that aim to simplify and revolutionize the concept of the vehicle, from a defined product to a definable experience. Distinguishing itself for technological excellence at an international level, TUC has achieved significant recognition, including exhibitions at CES in Las Vegas at the National Automobile Museum and recognition from major newspapers.
With the launch of TUC 3.0, the company is setting new standards in the industry by partnering with leading global OEMs. Learn more at www.tuc.technology.
Facebook @TUCtechnology
Instagram @tuc.technology
Twitter @TUCtechnology
Linkedin @TUC.technology
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424672317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
